Edwards Lifesciences
EW
Delayed Nyse - 11/22 10:01:48 pm
108.81USD
-0.65%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20162017
Sales2 9643 391
EBITDA8901 093
Operating profit (EBIT)8261 020
Pre-Tax Profit (EBT)--
Net income570789
EPS ( $ )2,613,60
Dividend per Share ( $ )--
Yield--
Announcement Date02/01/2017
09:15pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20162017
Debt--
Finance449256
Operating income (EBITDA)8901 093
Leverage
(Debt/EBITDA)
--
Capital Expenditure176147
Book Value Per Share (BVPS)12,3 $13,9 $
Cash Flow per Share3,23 $3,62 $
Announcement Date02/01/2017
09:15pm
-
Balance Sheet Analysis
Financial Ratios
Size 2017e 2018e
Capitalization 23 177 M$ -
Entreprise Value (EV) 22 921 M$ 22 452 M$
Valuation 2017e 2018e
P/E ratio (Price / EPS) 30,4x 26,6x
Capitalization / Revenue 6,84x 6,26x
EV / Revenue 6,76x 6,06x
EV / EBITDA 21,0x 18,3x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 7,89x 6,53x
Profitability 2017e 2018e
Operating Margin (EBIT / Sales) 30,1% 31,1%
operating Leverage (Delta EBIT / Delta Sales) 1,63x 1,42x
Net Margin (Net Profit / Revenue) 23,3% 24,0%
ROA (Net Profit / Asset) 15,5% 15,2%
ROE (Net Profit / Equities) 26,7% 23,9%
Rate of Dividend - -
Balance Sheet Analysis 2017e 2018e
CAPEX / CA   4,35% 3,87%
Cash Flow / Sales 22,6% 25,0%
Capital Intensity (Assets / Sales) 1,50x 1,58x
Financial Leverage (Net Debt / EBITDA) -0,23x -0,59x
Price Earning Ratio
BNA & Dividende